[go: up one dir, main page]

WO2015150921A3 - Methods for treating prostate cancer - Google Patents

Methods for treating prostate cancer Download PDF

Info

Publication number
WO2015150921A3
WO2015150921A3 PCT/IB2015/001187 IB2015001187W WO2015150921A3 WO 2015150921 A3 WO2015150921 A3 WO 2015150921A3 IB 2015001187 W IB2015001187 W IB 2015001187W WO 2015150921 A3 WO2015150921 A3 WO 2015150921A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostate cancer
treating prostate
subject
androgen receptor
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2015/001187
Other languages
French (fr)
Other versions
WO2015150921A2 (en
Inventor
Xavier SALVATELLA
Eva DE MOL
Carlos W. BERTONCINI
Christopher T.W. PHANG
Iain J. MCEWAN
Antoni RIERA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unversitat De Barcelona
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut de Recerca Biomedica IRB
University of Aberdeen
Original Assignee
Unversitat De Barcelona
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut de Recerca Biomedica IRB
University of Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unversitat De Barcelona, Institucio Catalana de Recerca i Estudis Avancats ICREA, Fundacio Privada Institut de Recerca Biomedica IRB, University of Aberdeen filed Critical Unversitat De Barcelona
Publication of WO2015150921A2 publication Critical patent/WO2015150921A2/en
Publication of WO2015150921A3 publication Critical patent/WO2015150921A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A method for inhibiting activity of the human androgen receptor in a cell, and a method for treating prostate cancer in a subject in need thereof, using a molecule which specifically inhibits interaction of amino acids 433-438 of the N-terminal domain of the receptor with the RAP74 subunit of TFIIF. A method of inhibiting androgen receptor activity in a cell, and a method for treating prostate cancer in a subject in need thereof, using an inhibitor of the phosphorylation of one or more residues of the N-terminal domain of the androgen receptor selected from the group consisting of: Ser422, Ser424, Ser426, Ser430, Ser431, Ser432, Thr435 and Thr438. A method of diagnosing a subject having, or at risk of having, castration-resistant prostate cancer, comprising determining the phosphorylation status of one or more of residues Ser422, Ser424, Ser426, Ser430, Ser431, Ser432, Thr435 and Thr438.
PCT/IB2015/001187 2014-04-03 2015-04-03 Methods for treating prostate cancer Ceased WO2015150921A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461974822P 2014-04-03 2014-04-03
US61/974,822 2014-04-03

Publications (2)

Publication Number Publication Date
WO2015150921A2 WO2015150921A2 (en) 2015-10-08
WO2015150921A3 true WO2015150921A3 (en) 2016-03-10

Family

ID=53761431

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/001187 Ceased WO2015150921A2 (en) 2014-04-03 2015-04-03 Methods for treating prostate cancer

Country Status (1)

Country Link
WO (1) WO2015150921A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023651A2 (en) 2017-07-28 2019-01-31 Massachusetts Institute Of Technology Small molecule modulators of the androgen receptor
WO2019023654A2 (en) * 2017-07-28 2019-01-31 Massachusetts Institute Of Technology Discovery of small molecules that target the androgen receptor and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054663A1 (en) * 2003-08-13 2005-03-10 Bennett Christina N. GSK-3 inhibitors
WO2006018633A1 (en) * 2004-08-17 2006-02-23 Imperial Innovations Limited Use of gsk-3 inhibitors for the treatment of prostate cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054663A1 (en) * 2003-08-13 2005-03-10 Bennett Christina N. GSK-3 inhibitors
WO2006018633A1 (en) * 2004-08-17 2006-02-23 Imperial Innovations Limited Use of gsk-3 inhibitors for the treatment of prostate cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALISON J. HOLE ET AL: "Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, no. 3, 20 December 2012 (2012-12-20), US, pages 660 - 670, XP055145617, ISSN: 0022-2623, DOI: 10.1021/jm301495v *
E. A. MOSTAGHEL ET AL: "Molecular Pathways: Targeting Resistance in the Androgen Receptor for Therapeutic Benefit", CLINICAL CANCER RESEARCH, vol. 20, no. 4, 15 February 2014 (2014-02-15), US, pages 791 - 798, XP055220529, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-12-3601 *
MANUJ TANDON ET AL: "New Pyrazolopyrimidine Inhibitors of Protein Kinase D as Potent Anticancer Agents for Prostate Cancer Cells", PLOS ONE, vol. 8, no. 9, 23 September 2013 (2013-09-23), pages e75601, XP055222794, DOI: 10.1371/journal.pone.0075601 *
OUMATA N ET AL: "Roscovitine-Derived, Dual-Specificity Inhibitors of Cyclin-Dependent Kinases and Casein Kinases 1", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 51, no. 17, 11 September 2008 (2008-09-11), pages 5229 - 5242, XP002544873, ISSN: 0022-2623, [retrieved on 20080813], DOI: 10.1021/JM800109E *
QING ZHU ET AL: "Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo", PROSTATE., vol. 71, no. 8, 1 June 2011 (2011-06-01), US, pages 835 - 845, XP055222884, ISSN: 0270-4137, DOI: 10.1002/pros.21300 *
RAYMOND J. ANDERSEN ET AL: "Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor", CANCER CELL, vol. 17, no. 6, 1 June 2010 (2010-06-01), US, pages 535 - 546, XP055223053, ISSN: 1535-6108, DOI: 10.1016/j.ccr.2010.04.027 *
TIMOTHY C. THOMPSON: "Grappling with the Androgen Receptor: A New Approach for Treating Advanced Prostate Cancer", CANCER CELL, vol. 17, no. 6, 1 June 2010 (2010-06-01), US, pages 525 - 526, XP055220515, ISSN: 1535-6108, DOI: 10.1016/j.ccr.2010.05.018 *

Also Published As

Publication number Publication date
WO2015150921A2 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
HK1246304A1 (en) Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
EP4410805A3 (en) Raav-based compositions and methods for treating amyotrophic lateral sclerosis
WO2015157252A8 (en) Treatment of cancer using anti-cd19 chimeric antigen receptor
WO2016100985A3 (en) Chimeric antigen receptors and methods of use thereof
WO2015153514A8 (en) Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
HK1231513A1 (en) Activin inhibitor response prediction and uses for treatment
NZ730123A (en) Processes and intermediates in the preparation of c5ar antagonists
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
EP3206304A4 (en) Echo cancellation device, echo cancellation program, and echo cancellation method
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
WO2016066634A3 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
MX2018016057A (en) Compositions and methods for treating cardiovascular disease.
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
WO2015009740A3 (en) Anti-mucin 1 binding agents and uses thereof
WO2015158890A3 (en) Pancreatic cancer therapy and diagnosis
WO2015153948A3 (en) Microtentacle imaging in patient tumor samples
WO2016079110A3 (en) Use of enzyme for cleaning
GB201620377D0 (en) Systems, methods, and kits for cleansing an ocular region
WO2015183943A3 (en) Inhibitors of fibroproliferative disorders and cancer
WO2016141334A9 (en) Compositions and methods for diagnosing and treating autoimmune diseases
WO2016167944A8 (en) Compositions and methods for treating autism
WO2017035176A8 (en) Method of preventing or treating obesity with an emc10 inhibitor
WO2015169973A3 (en) Marker sequences for diagnosing and stratifying systemic sclerosis patients
EP3092027A4 (en) Transpapillary methods and compositions for diagnosing and treating breast conditions
HK1201732A1 (en) Methods and compositions for treating and diagnosing acute myocardial infarction

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15744338

Country of ref document: EP

Kind code of ref document: A2